Vitamin D analogs modulate the expression of plasminogen activator inhibitor-1, thrombospondin-1 and thrombomodulin in human aortic smooth muscle cells

Journal of Vascular Research

Volumn 44, Issue 1, 2007, Pages 11-18

  Wu Wong, J Ruth ^a   Nakane, Masaki ^a   Ma, Junli ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Cardiovascular disease; Plasminogen activator inhibitor 1; Thrombomodulin; Thrombospondin 1; Vitamin D receptor

Indexed keywords

CALCITRIOL; CYTOCHROME P450 1A; MESSENGER RNA; PARICALCITOL; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOMODULIN; THROMBOSPONDIN 1;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; UPREGULATION;

AORTA; CALCITRIOL; CELLS, CULTURED; CYCLOHEXIMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENZYME INDUCTION; ERGOCALCIFEROLS; GENE EXPRESSION REGULATION; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN SYNTHESIS INHIBITORS; RECEPTORS, CALCITRIOL; RNA, MESSENGER; STEROID HYDROXYLASES; THROMBOMODULIN; THROMBOSPONDIN 1; VITAMIN D;

EID: 33846239981     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000097812     Document Type: Article

References (37)

1. Andress DL: Vitamin D treatment in chronic kidney disease. Semin Dial 2005;18:315-321.
2. Brown AJ, Dusso AS, Slatopolsky E: Vitamin D analogues for secondary hyperparathyroidism. Nephrol Dial Transplant 2002;17:10-19.
3. Carlberg C, Quack M, Herdick M, Bury Y, Polly P, Toell A: Central role of VDR conformations for understanding selective actions of vitamin D(3) analogues. Steroids 2001;66:213-221.
4. Zebrack JS, Anderson JL, Beddhu S, Horne BD, Bair TL, Cheung A, Muhlestein JB: Do associations with C-reactive protein and extent of coronary artery disease account for the increased cardiovascular risk of renal insufficiency? J Am Coll Cardiol 2003;42:57-63.
5. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ: Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004;15:1307-1315.
6. Martin KJ, Gonzalez EA: Vitamin D analogs: actions and role in the treatment of secondary hyperparathyroidism. Semin Nephrol 2004;24:456-459.
7. Nakai S, Shinzato T, Nagura Y, Masakane I, Kitaoka T, Shinoda T, Yamazaki C, Sakai R, Ohmori H, Morita O, Iseki K, Kikuchi K, Kubo K, Suzuki K, Tabei K, Fushimi K, Miwa N, Wada A, Yanai M, Akiba T: An overview of regular dialysis treatment in Japan (as of 31 December 2001). Ther Apher Dial 2004;8:3-32.
8. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-456.
9. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R: Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005;16:1115-1125.
10. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y: Lower risk for cardiovascular mortality in oral 1α-hydroxy vitamin D 3 users in a haemodialysis population. Nephrol Dial Transplant 2004;19:179-184.
11. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006;70:771-780.
12. Young EW, Albert JM, Akiba T, Greenwood R, Kimata N, W. LN, Piera L, Saran R: Vitamin D therapy and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2005;16:THPO0735.
13. Raggi P: Cardiovascular calcification in end stage renal disease. Contrib Nephrol 2005;149:272-278.
14. Amann K, Ritz C, Adamczak M, Ritz E: Why is coronary heart disease of uraemic patients so frequent and so devastating? Nephrol Dial Transplant 2003;18:631-640.
15. Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K: Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000;15:218-223.
16. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ: Atherothrombosis and high-risk plaque. 1. Evolving concepts. J Am Coll Cardiol 2005;46:937-954.
17. Laukkanen MO, Kivela A, Rissanen T, Rutanen J, Karkkainen MK, Leppanen O, Brasen JH, Yla-Herttuala S: Adenovirus-mediated extracellular superoxide dismutase gene therapy reduces neointima formation in balloon-denuded rabbit aorta. Circulation 2002;106:1999-2003.
18. Laszik ZG, Zhou XJ, Ferrell GL, Silva FG, Esmon CT: Down-regulation of endothelial expression of endothelial cell protein C receptor and thrombomodulin in coronary atherosclerosis. Am J Pathol 2001;159:797-802.
19. Yoshii Y, Okada Y, Sasaki S, Mori H, Oida K, Ishii H: Expression of thrombomodulin in human aortic smooth muscle cells with special reference to atherosclerotic lesion types and age differences. Med Electron Microsc 2003;36:165-172.
20. Tohda G, Oida K, Okada Y, Kosaka S, Okada E, Takahashi S, Ishii H, Miyamori I: Expression of thrombomodulin in atherosclerotic lesions and mitogenic activity of recombinant thrombomodulin in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1998;18:1861-1869.
21. Stenina OI, Krukovets I, Wang K, Zhou Z, Forudi F, Penn MS, Topol EJ, Plow EF: Increased expression of thrombospondin-1 in vessel wall of diabetic Zucker rat. Circulation 2003;107:3209-3215.
22. Wu-Wong JR, Nakane M, Ma J: Effects of vitamin D analogs on the expression of plasminogen activator inhibitor-1 in human vascular cells. Thromb Res, in press.
23. Nordt TK, Peter K, Ruef J, Kubler W, Bode C: Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease. Thromb Haemost 1999;82:14-18.
24. Kim AY, Walinsky PL, Kolodgie FD, Bian C, Sperry JL, Deming CB, Peck EA, Shake JG, Ang GB, Sohn RH, Esmon CT, Virmani R, Stuart RS, Rade JJ: Early loss of thrombomodulin expression impairs vein graft thromboresistance: implications for vein graft failure. Circ Res 2002;90:205-212.
25. Raugi GJ, Mullen JS, Bark DH, Okada T, Mayberg MR: Thrombospondin deposition in rat carotid artery injury. Am J Pathol 1990;137:179-185.
26. Vaughan DE: PAI-1 and atherothrombosis. J Thromb Haemost 2005;3:1879-1883.
27. Adams JC, Lawler J: The thrombospondins. Int J Biochem Cell Biol 2004;36:961-968.
28. Shah PK: Thrombogenic risk factors for atherothrombosis. Rev Cardiovasc Med 2006;7:10-16.
29. Waugh JM, Yuksel E, Li J, Kuo MD, Kattash M, Saxena R, Geske R, Thung SN, Shenaq SM, Woo SL: Local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model. Circ Res 1999;84:84-92.
30. Aihara K, Azuma H, Akaike M, Ikeda Y, Yamashita M, Sudo T, Hayashi H, Yamada Y, Endoh F, Fujimura M, Yoshida T, Yamaguchi H, Hashizume S, Kato M, Yoshimura K, Yamamoto Y, Kato S, Matsumoto T: Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem 2004;279:35798-35802.
31. Koyama T, Shibakura M, Ohsawa M, Kamiyama R, Hirosawa S: Anticoagulant effects of 1α,25-dihydroxyvitamin D 3 on human myelogenous leukemia cells and monocytes. Blood 1998;92:160-167.
32. Ohsawa M, Koyama T, Yamamoto K, Hirosawa S, Kamei S, Kamiyama R: 1α,25-dihydroxyvitamin D(3) and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized LDL. Circulation 2000;102:2867-2872.
33. Petrie MS, Harrell TE, Schwartz GG, Sane DC: Production of plasminogen activator inhibitor-1 (PAI-1) by endothelial cells: differential responses to calcitriol and paricalcitol. J Thromb Haemost 2004;2:2266-2267.
34. Sajid M, Hu Z, Guo H, Li H, Stouffer GA: Vascular expression of integrin-associated protein and thrombospondin increase after mechanical injury. J Investig Med 2001;49:398-406.
35. Bailie GR, Johnson CA: Comparative review of the pharmacokinetics of vitamin D analogues. Semin Dial 2002;15:352-357.
36. Ritter CS, Armbrecht HJ, Slatopolsky E, Brown AJ: 25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int 2006;70:654-659.
37. 3. Cancer Epidemiol Biomarkers Prev 1998;7:391-395.